The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning DCR,
I think he might be working flat out to increase the value of shareholders which will increase the value of his circa 34% shareholding.
OR,
He might be sunning himself looking at the 100m gbp yacht brochures, who knows?
vbw
They (We) have an asset and also £1m in cash which was extracted from Tiziana (Shraeholders), by way of a capital reduction, so there is no need for another to buy into the demerger.
Wher is the value for accustem coming from.? Surely another business will have to buy into the de merger in order to give the shares value? Or have I got it wrong?
Yes, the way the Accustem listing has been handled is indeed a joke, and the joke is on us
Take it this is a joke
I do not expect any news on Accustem. The Company and its Broker/Advisor are clearly not capable of acknowledging its corporate commitments. The treatment of Shareholders and the deliberate lack of responses by IR is this regard has been shocking. In the unlikely event I get my Accustem shares allocation I will sell immediately because I have no interest in a Company which has such a disregard for its Shareholders.
Hi. Tiziana don’t, I agree....but doesn’t Accustem? It’s not listed at the moment and can’t list without being a plc can it, which needs a special res?
They don't need a GM. It got passed to demerge to a listed company last year. So they don't need another special resolution.
Hi. Holder for over 12m now.
I emailed Willy Simon at the company regarding the PSC register at companies house. There haven’t been any updates in the required timeframe under CA2006. Tiziana is still showing for Accustem and Stemprinter which isn’t correct. I haven’t had a response. They do need to respond within 5 business days for a formal request, which mine wasn’t.
Also, for the Q1 deadline to be met the exchange needs to be notified within 10 working days of 31st Mar. That’s the 17th. We need a special res to change Accustem to a plc from a limited company. That’s 14 days for a gm as well. Which means we need to get a notice of meeting tomorrow, 3rd, to hit?
Thanks to everyone’s comms on this board.
Rokerpark68, Great post as usual which totally echo my summary of the company.
A further blow to the shareholders will probably be a sell off when Accustem eventually lists to compensate for the shocking Tiziana SP performance. Shocking when you consider all the momentum and positive sentiment that Stemprint had at the time of demerger which has now been totally wasted.
Just a standard demerger would have been the solution and not what now appears to be a GC vanity project
There was a date you had to hold them bye last year, most people sold after that date and will still be entitled to the stem share
@MIKESM
Thanks for your post - very helpful.
I have emailed a couple of times about the Accustem situation over the past two weeks without a response. I decided to make a call today and spoke to Hana Malik who I have to say was perfectly charming. She told me that regrettably there is very little the company is allowed to divulge in specific terms about the IPO progress, but was able to confirm that Tiziana and Accustem has provided everything that is required as part of the floatation process and now the timing of the next stage is out of their hands. Having said that, she does remain optimistic that the Q1, 2021 timescale may be met.
I then enquired about the Phase II trial of the nasally administered Foramulab covid treatment that appears to have been so effective in Brazil, and was not surprised to hear that she is not at liberty to divulge any specific information other than, as has previously been confirmed, they anticipate the trials will take place in more than one country.
For what its worth my instinct is that this is a company that has people with tremendous professional knowledge and experience behind it, and the potential applications for Foramulab and Milciclib are truly huge. From the impressive results of last year's Royal Marsden trial, StemPrinter/ Accustem appears also has enormous potential. My conclusion, frustrating though it may be, is to just be patient and sooner or later, exceptional rewards in increased shareholder value will arrive. Of course Gabrielle Cerrone has most to gain if and when that happens, a fact that also fills me with confidence....
I feel like there is lots happening with this guys!
They keep getting sidetracked and not completing anything!.
Hi Greend100
As much as I am committed to TILS I agree that the board makes its life complicated and this, ultimately, can start to detract from the company's very positive pipeline narrative.
This would be easy to address in normal circumstances if there were influential non-executive directors and assertive institutional investors involved. As I have mentioned before, the company needs a strong Chief Operating Officer, a higher profile Chief Financial Officer and heavier-hitting financial advisers, brokers and financial PR. Another properly independent Non-Executive Director would help as well.
The reason these obvious corporate moves haven't been made is that GC is effectively in control with his 34% shareholding (combined no doubt with a handful of other friendly shareholders) and he doesn't see the need to make changes.
One thing we would all like to see is more institutional investor interest in TILS which could be of real benefit to the share price, but with the current shareholding structure and limited scope for new investors to take meaningful positions, I think this is unlikely.
Having stated all of the above, I stay invested because the potential upside from the therapeutic portfolio could be very exciting - so I accept there is a trade-off here. Perhaps this trade-off is part of the reason for the TILS share price performance.
Does anyone know if/when the Covid treatment (inhalers) is approved, if it's then possible for a GP in this country to buy some for their patients? (I'd like some (now))
And do you think the NHS will pounce on it to free up hospital beds?
I also want my Accustem shares NOW!
Hi Green,
I'm not too worried about Accustem and like you I can't quite decide on what is causing the delay.
On the Covid data, we had a few mixed messages in terms of length of time. i'm sure I heard/read 2 weeks, then a few weeks. Well it has now been 4 weeks, and we still wait.
Anyway, I had some money become available in my SIPP today, so really couldn't turn down 109 this morning !
Hi FFF, less bothered about the Covid data...that could always have been a few weeks from top-line date, would be nice though if it was accompanied by next steps rather than in isolation.
Accustem, a different scenario. I can live with the lack of liquidity, it's more the frustration that they make their lives complicated, dual listings, spin offs, Okyo etc... but don't beef up the resource to support it.
Having said that, having waited this long would rather they listed with accompanying news, CE approval etc... rather than it being a damp squib. Can't decide if it's a potential sale, accreditation or disorganisation causing the delay (noting ADRs have been mentioned as an issue suspect the latter).
Davey & legalwolf
"I would suggest that everyone goes onto the Tiziana Life Sciences website and clicks on the Contact page, then sends a polite inquiry. "
6th of Jan I did this asking the two questions that legal wolf suggested.
Under the nasdaq "due bill" process it would mean that although the record date has passed the ex date hasn't.
So I asked the following questions:
1. If I sell my adr shares today which have been held over a year will I still get accustem shares as they were held past the record date?
2. If I buy adr shares today and keep them long term will I get accustem shares even though I have bought after the record date. If so why? Is this because of the due bill process on the nasdaq.
I followed up with several phone calls over a few weeks. When talking to them , they knew my email right away and said they didn't know the answer and they were investigating it. They said that the due bill process on the nasdaq made it much more complex than the uk traded share.
I also followed up with more emails chasing, I never received a single reply or acknowledgement.
In frustration I sent them a stronger email about 3 weeks ago saying that they really have to know themselves the answer to the questions, otherwise they are trading a stock that an investor can't value because even the company itself doesn't know, and continuing to trade a share in this manor breaches nasdaq rules as there can be no doubt the market is confused if the company itself is.
I do love the company but I do find all of this extremely poor.
Agree with you Davey though sounds like Interactive Investor have been sending messages with no response which is also very poor given they trade the shares on both behalf of the individual and the company.
I don't like to bash a share that i'm invested in, but Davey is right !
Very poor this, even the 2nd set of Covid data was promised and and has been missed
Biotech investing is full of disappointments on the clinical and regulatory side but sometimes I get the impressions Tiziana is run as a lifestyle business to some degree, with little regard to Shareholders. On the corporate action side missing the odd deadline is fine, but Investors expect updates if deadlines or targets will be missed. Radio silence is not acceptable for a Main Market Listed Company. If you move to the Main Market stop behaving as if you are still on AIM.
This whole saga seems to have been really poorly thought out. Missed one target date last year ( Q4 ) and surely going to miss a second one now as can't see an IPO going ahead this month. Very very disappointing.
I would suggest that everyone goes onto the Tiziana Life Sciences website and clicks on the Contact page, then sends a polite inquiry. Someone suggested Accutsem is now nothing to do with Tiziana since the demerger - that is partially correct but Tiziana's capital reduction means the Company still has an obligation. If they didn't Companies would be hiving off all sorts of assets without any form of recourse.
The one thing tils fall down on is time.
If you make predictions keep to them .
Brazil drug is another example not starting trials.